BioMarin’s gene therapy treatment receives EU approval

The European Medicines Agency (EMA) has approved BioMarin’s gene therapy for the treatment of hemophilia A. The news comes shortly after an external expert committee unanimously recommended the U.S. Food and Drug Administration (FDA) to approve two of bluebird’s gene therapy treatments. For Swedish CombiGene, which has a collaboration with american company Spark Therapeutics, all regulatory successes in the sector are welcome news. BioStock reached out to CEO Jan Nilsson for a comment.